Table 5 Neutralization of the Omicron variant BA.1 by the EUA-granted therapeutic Abs
IC50 (ng/mL) for Omicron BA.1 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Antibody | Epitope | Peking U. [210] | Vir Biotech [199] | Columbia U. [248] | Göttingen U. [249] | Washington U. [188] | Oxford U. [249] | Université de Paris [250] | Tokyo U. [187] | The U.S. NIH [185] |
Casirivimab | RBM | > 10,000 | > 10,000 | > 10,000 | > 1,000 | > 10,000 | > 10,000 | > 9,000 | 14,110 | > 10,000 |
Imdevimab | RBD | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 9,000 | > 50,000 | > 10,000 |
REGEN-COV (Casirivimab + Imdevimab) | N.D | > 10,000 | > 10,000 | > 1,000 | > 10,000 | N.D | > 9,000 | > 10,000 | N.D | |
Bamlanivimab | RBD | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 9,000 | > 50,000 | > 10,000 |
Etesevimab | RBM | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 10,000 | > 9,000 | > 50,000 | > 10,000 |
Bamlanivimab + Etesevimab | N.D | > 10,000 | > 10,000 | > 10,000 | > 10,000 | N.D | > 9,000 | > 10,000 | N.D | |
Xevudy Sotrovimab | RBD | 181 | ~ 200 | 100 ~ 1,000 | 100 ~ 1,000 | 373 | 256 | 917 | 373 | 281 |
Cilgavimab | RBM | 2,178 | 2,772 | ~ 1,000 | N.D | 381 | 3,488 | 1,213 | 443 | 5850 |
Tixagevimab | RBM | 6,860 | > 10,000 | 100 ~ 1,000 | N.D | 913 | 1,152 | 8,305 | 1,299 | 269 |
Evusheld (Cilgavimab + Tixagevimab) | N.D | 418 | 10 ~ 100 | N.D | 147 | 273 | 773 | 225 | N.D | |
Regdanvimab | RBM | N.D | > 10,000 | N.D | N.D | > 10,000 | N.D | > 9,000 | N.D | > 10,000 |
Bebtelovimab | RBD | N.D | N.D | N.D | N.D | N.D | N.D | N.D | N.D | 5.1 |
Approach | Pseudovirus | Pseudovirus | Pseudovirus | Pseudovirus | Authentic virus | Authentic virus | Authentic virus | Authentic virus | Pseudovirus | |